Sanofi Consumer Healthcare India Q4 Results 2025 on 21 Feb, 2025: Revenue decreased by 20.53% YoY & profit decreased by 34.66% YoY, profit at ₹44.3 crore and revenue at ₹170.7 crore.

For over a thousand people who undergo a stem cell or bone marrow transplant, survival comes at a cost: graft-versus-host ...

This week, the European Commission granted approval to Merck’s MRK novel HIF-2α inhibitor, Welireg, for two indications. The ...

Paris: Sanofi and CD&R have announced that they have signed the share purchase agreement in relation to the sale of a 50 ...

The Board of Directors of Sanofi Consumer Healthcare India Limited has recommended a final dividend of Rs. 55/- per equity share having face value of Rs.10/- each for the Financial Year ended 31st ...

The company faced headwinds in the December 2024 quarter (Q4) as it reported a significant decline in earnings.

Sanofi Consumer Healthcare India has reported 1% rise in net profit to Rs 46.35 crore on a 6.8% increase in net sales to Rs 170.70 crore in Q3 FY25 as compared with Q3 FY24.

Meanwhile, USFDA has conducted a current good manufacturing practices (cGMP) inspection at the analytical testing facility of Sitec Labs, wholly owned subsidiary of the Company (Sitec) located in ...